"We are pleased to welcome Todd to the
Mr. Nichols most recently held the position of Vice President, Marketing and Sales, Inflammation and Immunology at
"I am excited to join a company with strong leadership, dedicated employees and that is rooted in its mission to make a positive impact on patients struggling with central nervous system (CNS) disorders," said Mr. Nichols. "I look forward to working with my new colleagues as the company continues to evolve to meet the needs of a complex treatment landscape."
Mr. Nichols began his career in 1997 at Schering-Plough (acquired by Merck in 2009), where he held a variety of sales and marketing positions across multiple therapeutic franchises. While at Merck, Mr. Nichols served in numerous senior roles including Vice President and Head of the U.S. Vaccine Business Unit. Mr. Nichols joined Biogen in 2014 as Vice President, U.S. Sales and Field Operations, and achieved record sales for three consecutive years.
He holds a bachelor's degree in accounting from
About Alkermes
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's future performance, business plans or prospects, and expected growth; and the potential therapeutic and commercial value of the company's products. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties, including those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2018 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (
Alkermes Contacts: |
||
For Investors: |
Sandy Coombs, |
+1 781 609 6377 |
For Media: |
Matthew Henson, |
+1 781 609 6637 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-appoints-industry-veteran-c-todd-nichols-as-senior-vice-president-of-sales-and-marketing-300837694.html
SOURCE